© 2020 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2020 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Targeted Oncology is actively following as the COVID-19 pandemic develops.
Robert Alter, MD, describes the rationale for treating a 58-year-old male with advanced renal cell carcinoma with the combination of lenvatinib and everolimus following progression on first-line therapy.
In this episode of Targeted Talks, experts discuss the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings.
Atezolizumab in combination with bevacizumab, carboplatin, and paclitaxel continues to prolong progression-free and overall survival in EGFR-mutant NSCLC.